https://scholars.lib.ntu.edu.tw/handle/123456789/548917
標題: | Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions | 作者: | Chou Y.-H. JA-DER LIANG Wang S.-Y. SHIH-JER HSU Hu J.-T. Yang S.-S. Wang H.-K. Lee T.-Y. Tiu C.-M. |
關鍵字: | Contrast agent; focal liver lesions; microbubble; perfluorobutane; safety; Sonazoid; ultrasound | 公開日期: | 2019 | 出版社: | Wolters Kluwer Medknow Publications | 卷: | 27 | 期: | 2 | 起(迄)頁: | 110 | 來源出版物: | Journal of Medical Ultrasound | 摘要: | Background: The purpose of this study was to report the safety of perfluorobutane (Sonazoid) as a vascular-phase imaging agent in characterizing focal liver lesions (FLLs). Materials and Methods: From May 2014 to April 2015, a total of 54 individuals who received Sonazoid contrast-enhanced ultrasound (CEUS) were enrolled at 5 hospitals of 4 medical centers. All individuals were included in safety evaluation. A prospective study to evaluate the adverse effect (AE) incidences after intravenous administration of Sonazoid. Results: Sonazoid was well tolerated. Treatment-emergent adverse events (TEAEs) representing AE were recorded for 13 (24.1%) patients. The most common AE was abdominal pain (9.3%), followed by heart rate irregularity (5.6%). The majority of these patients (69.2%) experienced TEAEs that were mild in intensity. Sonazoid causes no significant AEs after intravenous injection. The only noteworthy AEs are related to tolerable myalgia (3.7%), abdominal pain (1.9%), and headache (1.9%). None of the 54 patients showed serious adverse effects. Conclusion: Sonazoid shows good safety and tolerance of intravenous use during CEUS of the liver for evaluation of FLLs. ? 2019 Journal of Medical Ultrasound | Published by Wolters Kluwer-Medknow. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068597411&doi=10.4103%2fJMU.JMU_44_19&partnerID=40&md5=36e6e82504fea21ffa932edec36945c1 https://scholars.lib.ntu.edu.tw/handle/123456789/548917 |
ISSN: | 0929-6441 | DOI: | 10.4103/JMU.JMU_44_19 | SDG/關鍵字: | perflubutane; abdominal pain; abnormal blood pressure; anemia; Article; contrast-enhanced ultrasound; drug safety; drug tolerability; female; gastrointestinal disease; headache; heart arrhythmia; heart rate; human; liver injury; major clinical study; myalgia; pancytopenia; phase 3 clinical trial; prospective study; vascular disease |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。